Handelsbanken Fonder AB Has $6.22 Million Stock Position in Illumina, Inc. $ILMN

Handelsbanken Fonder AB reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,400 shares of the life sciences company’s stock after selling 4,200 shares during the period. Handelsbanken Fonder AB’s holdings in Illumina were worth $6,217,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after purchasing an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new position in Illumina during the third quarter valued at approximately $2,319,000. Caprock Group LLC acquired a new position in Illumina during the third quarter valued at approximately $1,479,000. Rakuten Investment Management Inc. acquired a new position in Illumina during the third quarter valued at approximately $861,000. Finally, Capital World Investors raised its position in Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.3%

Shares of NASDAQ:ILMN opened at $144.41 on Friday. The company has a fifty day moving average of $130.45 and a 200-day moving average of $130.91. The company has a market capitalization of $21.85 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 104,393 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the sale, the director owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. The trade was a 2.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Royal Bank Of Canada initiated coverage on shares of Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price objective for the company. Citigroup upped their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Robert W. Baird set a $137.00 price target on shares of Illumina in a report on Friday, February 6th. Guggenheim upped their price target on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.